NEU neuren pharmaceuticals limited

The Glypromate failure, page-3

  1. 920 Posts.
    lightbulb Created with Sketch. 254
    Correct but no point having the safest drug in the world if it has no efficacy - safety is pretty much a given - no dropouts and at AGM , numerous FDA meetings re safety had nothing to report. Secondary endpoints are the key. Going from the medical journal of FB there are compelling stories - but unfortunately at the moment they are just that. In saying that with an A-grade management team , strong trial design and numerous measurable secondary endpoints I'm quietly confident. We hav a lot of the right boxes ticked vs the other failed biotechs. Can't really compare them and there failures.

    Not long now either way - if positive the flood of $$ into this will send the SP into the stratosphere
    Last edited by lilypily: 28/10/14
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$13.88
Change
-0.140(1.00%)
Mkt cap ! $1.727B
Open High Low Value Volume
$13.90 $14.21 $13.64 $4.590M 329.8K

Buyers (Bids)

No. Vol. Price($)
1 600 $13.85
 

Sellers (Offers)

Price($) Vol. No.
$13.96 2894 1
View Market Depth
Last trade - 16.10pm 08/07/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.